ABSTRACT “A journey of mixed emotions” is a quote that best describes the progress chart
of vascular endothelial growth factor receptor (VEGFR) inhibitors as cancer therapeutics in …

VEGFR, a receptor tyrosine kinase inhibitor (TKI), is an important regulatory factor that
promotes angiogenesis and vascular permeability. It plays a significant role in processes …

Angiogenesis inhibitors have produced significant advances in the treatment of several
tumors including colorectal, lung, ovarian and renal carcinomas. These agents, however …

Introduction: Angiogenesis is an important component of certain normal physiological
processes, but aberrant angiogenesis contributes to some pathological disorders and in …

VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma,
gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a …

Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key
roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been …

Tumor angiogenesis has always been a major gap for effective cancer therapy. Interruption
of aberrant angiogenesis by specific inhibitors targeting receptor tyrosine kinases (RTKs) …

Vascular endothelial growth factor receptor (VEGFR) is an important receptor tyrosine
kinase (RTK) in the induction of angiogenesis. Abnormal activation of VEGFR leads to …

Computational and experimental studies were applied to the discovery of a series of novel
vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors. Eight compounds …

New blood vessels formation from the existing vasculature is called angiogenesis. It is an
essential physiological process for the growth of cells, tissue repair, wound healing, and …